台灣醫療暨生技器材工業同業公會
收 109.03.16 文
檔號: 109155

財團法人工業技術研究院　函

地址：310401 新竹縣竹東鎮中興路 4 段 195 號
承辦人：李芝瑩
電話：03-5912142
E-mail：stacylee@itri.org.tw

109000416411

241 新北市三重區重新路 5 段 609 巷 6 號 3 樓之 3

受文者：台灣醫療暨生技器材工業同業公會
發文日期：中華民國 109 年 03 月 12 日
發文字號：工研生字第 1090004164 號
速別：速件
密等：無
附件：如文

主旨：為科技部主辦，本院執行之「科學園區生醫創新聚落整合推動委託計畫」項下之「SmartLabs 全球啟動計畫」及「Janssen-Taiwan 合作計畫」進行徵案公告，惠請協助轉知貴會會員朋友，廣宣周知。

說明：

一、「SmartLabs 全球啟動計畫」及「Janssen-Taiwan 合作計畫」二項徵案計畫係本院承接科技部「科學園區生醫創新聚落整合推動委託計畫」之項下業務，目的為進行國際連結，促成國際產學合作，打造台灣品牌形象。提供申請須知、徵案公告，惠請協助轉知所屬於各相關管道廣宣周知，請查照。

二、參考網站

SmartLabs 全球啟動計畫 https://reurl.cc/X66qn0

Janssen-Taiwan 合作計畫 https://jti.itri.org.tw/apply.aspx

三、各計畫聯絡人

SmartLabs 全球啟動計畫 陳進富博士，電話：03-591369

5，MAIL：FrankCFChen@itri.org.tw

Janssen-Taiwan 合作計畫 邱小容小姐，電話：03-59137

40，MAIL：jtioffice@itri.org.tw

正本受文者： 台灣醫療暨生技器材工業同業公會

院長 劉文雄

依權責劃分規定授權業務主管決行

「SmartLabs 全球啟動計畫」

培訓徵件簡章

一、 簡介與目的：

科技部辦理「科學園區生醫創新聚落整合推動計畫」，引進國際級加速器SmartLabs（以下簡稱SLs）在新竹生醫園區建構生醫新創基地執行「SmartLabs 全球啟動計畫」，每3個月辦理一梯次之新創加速培訓，參訓團隊可爭取前往SLs美國波士頓基地接受移地實戰訓練。培訓內容包含專利與法規佈局、募資與財務規劃、及國際行銷與通路等並媒合國際資金，促成與國際指標性大廠實質商業合作。

二、 指導與主辦單位：

指導單位：科技部

主辦單位：SmartLabs國際生醫加速器

協辦單位：財團法人工業技術研究院生醫與醫材研究所

三、 培訓領域：

生技製藥與醫療器材研發成果或衍生之新技術或新應用，如再生醫學（細胞/免疫治療）、精準醫學、智慧健康與醫學影像、新藥開發……等。

四、 培訓地點：

新竹生醫園區 SmartLabs 國際生醫加速器(筑波大樓)及SmartLabs在美國波士頓之場域。

五、報名資格 (以下條件擇一)：

(一) 在台灣設立登記之公司(公司核准設立日期為102年1月1日

後)，且公司代表人為本國籍；若為籌備中之公司應擬具切結書，於培訓開始前完成公司設立登記。

(二) 五年內曾入選參與科技部價創計畫、法人鏈結計畫、研發成果萌芽計畫、創新創業激勵計畫、應用型研究育苗專案計畫、生醫商品化中心、台灣—史丹福醫療器材產品設計之人才培訓計畫(STB)、生醫與醫材轉譯加值人才培訓-ANCHOR UNIVERSITY計畫(SPARK Taiwan)以及科技部國際產學聯盟(GLORIA) 推薦之團隊。

六、培訓及報名方式：

(一) 「SmartLabs 全球啟動計畫」採兩階段培訓，第一階段為在台培訓，第二階段為美國移地實戰訓練。

(二) 第一階段培訓，報名參訓者每一團隊人數以5人為限。

(三) 同一團隊一年僅得申請一次。

(四) 第一梯次錄取名單將於109年3月25日於科技部官網公告。

(五) 申請團隊經書面審查合格，將通知繳交培訓費用（含參訓保證金5萬元）新台幣10萬元整，完成第一階段培訓後將無息退還參訓保證金5萬元整。

(六) 主辦單位將每月依團隊在台培訓成績(培訓狀況與完成度)，將列入美國實戰演練之甄選評定參考。

(七) 獲主辦單位及科技部審查通過之團隊可參加美國波士頓移地實戰演練，每梯次為期3個月，每團隊員額以3人為限，機票、住宿及生活費用需由團隊自理。

(八) 獲選參加美國實戰演練之團隊應於實戰演練開始前取得簽證。

七、預定培訓時間 (109年)：

(一)在台培訓：

梯次	報名日期	培訓時間
第一梯次	即日起至 3月 13日 下午 5 點止	3 月 30日至 6月30 日
第二梯次	5 月 4日至 6月 4 日 下午 5 點止	7月 1 日 至 9月24日
第三梯次	8 月 3 日至9月 3 日 下午 5 點止	10 月 1 日 至 12 月24日

(二)美國移地實戰訓練：

1. 預計辦理三梯次美國波士頓移地實戰訓練，每梯次預計時程為3個月。
2. 第一梯次美國波士頓移地實戰訓練時間預計為109年4月至7月。

八、報名資料：

(一) 報名表(應含團隊基本資料、技術/產品簡介、發展階段等內容)。

(二) 10 至 20 頁英文簡報 PDF 檔，需包含團隊的成員介紹、目標市場之評估、核心技術與智財布局、商業模式、及商業發展計畫、和資金需求與里程碑。

(三) 相關證明文件：已完成設立公司之團隊，應提供公司登記證明文件、曾參與科技部計畫之團隊，應提供合約書影本或其他相關證明文件。

(四) 智慧財產證明文件。

(五) 其他證明文件，如：獲獎證明、推薦函、團隊成員英文能

力證明...等。

(六) 報名資料請以電子檔 E-mail寄至 FrankCFChen@itri.org.tw 陳進富博士收。 聯絡電話: 03-591-3695。

九、 國內培訓評選標準：

評選項目	考慮因素	配分
市場潛力	● 產品/技術定義與定位 ● 關鍵技術發展現況與產品規劃時程 ● 市場競爭性 ● 臨床潛力	30
投資價值	● 臨床價值。 ● 技術/產品之現況與國際競爭力。 ● 預期市場價值。 ● 專利狀態。	30
商業模式	● 商業模式之合理性 ● 商業模式之估算方式	20
團隊之優勢	● 新創團隊組成及經歷 ● 新創團隊之概況及簡要敘述。 ● 團隊相關之經驗與實績。	10
其他	● 其他可資評估之項目(獲獎證明或推薦文件等)。	10
總配分		100

十、 參訓團隊應履行之事項：

(一) 獲選第一階段在台培訓之團隊需於通知期限內繳交培訓註冊費(含參訓保證金)新台幣10萬元整。

(二) 團隊需全程參與本計畫所有培訓課程、輔導、與媒合交流會等相關活動 (單一成員得請假，惟時數不得超過總時數1/5)。

(三) 團隊完成國內培訓，並繳交完訓報告書參加成果發表會後，得申請退回參訓保證金新台幣5萬元整。

(四) 參加美國實戰訓練之團隊應與SmartLabs簽立場地使用契約，並切結遵守美國當地法令及SmartLabs之行為規範。

(五) 團隊培訓員額超過計畫所訂補助限制者，相關費用由團隊自行負擔。

(六) 參訓團隊需配合科技部提供團隊或公司成立後營運經驗、營運績效、募資情況等相關說明與資料，並配合本培訓計畫相關研究訪談。

(七) 參訓團隊應無償配合提供培訓歷程與相關成果之介紹文字、影音、照片等，並授權科技部使用。

※主辦單位保有上述計畫內容、條文與活動時程變更及解釋之權利。未盡事宜，依相關法令規定辦理。 最新訊息請以科技部網站公佈為主。

科技部「SmartLabs 全球啟動計畫」
台灣培訓徵件報名表(※請以中文或英文填寫)

公司名稱 (Company)	(中) (英)	
成立背景,資本額及成立日期 (Background, Registered capital and Founded Date)	(中) (英)	
參訓名單(中文) (Team Members)	姓名(Name)/職稱(Position)	聯絡資訊 (Contact Information)
		E-mail: Tel:
公司發展階段 (Development status)		
成就或獎項 (Achievements)		
公司產品或技術 (Products)		
智慧財產 (Intellectual property)		
適應症 (Indication/ Intended use)		
參訓目的及目標 (Purpose and Objectives)		
商業模式 (Business Model)		

Janssen-Taiwan 合作計畫 - 2020 研究案徵求公告

（ITRI 2020 Grant Call in Collaboration with Janssen）

- **主辦單位： Janssen Biotech, Inc. (下稱：Janssen)**

  工業技術研究院(下稱：工研院)

徵案宗旨

美國 Janssen Biotech, Inc.（Janssen）一直致力於疾病早期治療之相關研究。為了整合技術創新與商業模式，追求更顯著的早期治療效果，以推動醫療保健的新典範，因而發起“Janssen-Taiwan 合作計畫”。

工研院生醫所基於推動台灣生醫科學研究發展之宗旨，也為提升台灣研究單位、企業、醫院、學校與國際企業、研究機構合作之經驗值，以及增進台灣生醫產業相關技術創新之附加價值與國際競爭力，在科技部與經濟部共同支持之下，與 Janssen 共同投入經費執行本徵案計畫。為執行“Janssen-Taiwan 合作計畫”所需，並由工研院發布“Janssen-Taiwan 合作計畫 - 2020 研究案徵求公告”（以下稱：本徵案計畫）。

參加資格

中華民國設立登記之大學、研究所、醫院、其他學術研究機構、新創事業、企業、法人及其所屬單位（包括工研院各研究所）或由前述各機構跨界合作組隊者，均可提案(下稱：提案團隊)。

請注意提案團隊必須填寫完成附件 A 的 Healthcare Compliance Screening Questionnaire 且需通過資格篩選，以確認是否符合參加資格。

時程規劃

徵案時間	即日起至 2020 年 5 月 14 日
徵選結果通知	預計 2020 年 8 月 18 日
獲選計畫簽約	預計 2020 年 11 月 21 日

- **活動相關資訊請連結** https://jti.itri.org.tw/index.aspx **網站查詢。**

ITRI 2020 Grant Call in Collaboration with Janssen

➢ Sponsors： Janssen Biotech, Inc. (Janssen)

Industrial Technology Research Institute (ITRI)

➢ Program Objectives and Description

The purpose of the "ITRI 2020 Grant Call in Collaboration with Janssen" (the "Event") as initiated by Janssen is to integrate breakthrough science with commercial innovations to effectively intercept disease prior to onset, improve patient outcomes and catalyze a new paradigm in healthcare.

Sharing joint interest to advance life science research and development activities in Taiwan, ITRI, with the support of relevant governmental departments, will implement this call for proposal in collaboration with Janssen. This presents a great opportunity for Taiwan's research institutes, enterprises, hospitals, and schools to collaborate with world-class enterprises, and add value to existing technological innovations within Taiwan's biomedical industry. ITRI, together with Janssen, aims to collectively select proposals to receive funding up to an aggregate of one million U.S. dollars (US$1,000,000) (each proposed research plan shall not span more than three (3) years from the date of funding).

➢ Applicant Eligibility

Applicants herein should be companies, foundations, universities, institutions of higher learning (including ITRI's laboratories), hospitals, or other corporations, which are established and existing under the laws of the Republic of China (Taiwan). A cross-team composed of any entities aforementioned is more than welcome. Please note that all Applicants must complete the healthcare compliance screening questionnaire attached hereto as Exhibit A and shall be subject to healthcare compliance screening for eligibility to receive funding.

➢ Timetable（expected deadline）

Proposal Submission Deadline	May 14th, 2020
Decision Notification	August 18th, 2020
Research Agreement Execution	November 21st, 2020

➢ Event details can be found at https://jti.itri.org.tw/index.aspx

➢ Topics (Technology Area)

The Sponsors are seeking proposals that address one of the following focused problem statements and have potential in resolving any one of the below problems:

Focused Disease Areas:

1. Lung Cancer /AI
2. Infectious Diseases
3. Healthy Baby / Big Data
4. Disease Prevention / Big Data / AI

Significant Problems to be studied:

1. Lung Cancer /AI
   - How can people with lung cancer be identified earlier through other than the conventional approaches (i.e. CT medical imaging)
   - How can people with a high-risk to lung cancer be identified and how can these individuals be protected?
   - How can digital therapeutics, such as virtual reality or gamification, potentially reduce the number of people with lung cancers who are smoking?
2. Infectious Diseases
   - What are novel non-vaccine technologies (targeting the virus or the host) which can be used for effective long-lasting prevention of viral respiratory tract infections?
3. Healthy Baby / Big Data
   - How can we predict which infants will get early life diseases, e.g. atopic dermatitis, asthma, allergy before they appear?
   - What new non-invasive devices can be used on infants to help detect / monitor disease?
   - What nutritional solutions can be used to help aid in the infant's development?
4. Disease Prevention / Big Data / AI
   - What non-invasive devices can be used to help detect changes in an adult health?
   - How can wearable devices and sensors monitor the health of an adult?
   - What types of home diagnostics can be used to monitor the health of an adult or family?
   - In general, how can big data be applied to diagnose disease before it happens?

➢ Proposal Documents:

Please submit your proposal electronically prior to 17:00 by **14th May (Thursday), 2020** to the following email: jtioffice@itri.org.tw. The proposal should be titled "ITRI 2020 Grant Call in Collaboration with Janssen" and should include the following information: applicant's name, proposal title, contact person, principal researcher and his/her position. Please include the following attachments in your Proposal(s):

1. Brief biography of the principal researcher of the Applicant;
2. State of development of the technology under the Proposal;
3. Non-confidential abstract, description and keywords applicable to the Proposal;
4. Proposed application and/or relevance to the Technology Area;
5. Proposed budget (including overhead/indirect costs), in-kind contributions to be made by the applicant, milestones and proposed completion date (based on receipt of requested funds);
6. Completed health care compliance questionnaire set forth in Exhibit A;
7. An affirmative or negative confirmation as to whether Applicant agrees to the material terms and conditions of the Research Agreement set forth in Exhibit B. For the avoidance of doubt, a negative confirmation of the material terms and conditions of the Research Agreement will still be reviewed by the Sponsors;
8. Executed Statement Against Corrupt Practices in the form attached hereto as Exhibit C;
9. Executed Statement of Compliance with Federal Animal Welfare Regulations in the form attached hereto as Exhibit D.
10. Executed "Notification and Consent Regarding Collection, Processing and Use of Personal Information" in the form attached hereto as Exhibit E by Applicant's each member.
11. Statement that the Applicant has no material relationship with a competitor of Janssen or its affiliates, including any J & J affiliate.

➢ Funding Notice

These Proposal Documents will be reviewed by a committee organized by the Sponsors (the "Committee") according to the Application Instructions (please find Application Instructions in "Other References" at https://jti.itri.org.tw/index.aspx). Applicants who enter final election will give an oral presentation in front of the Committee. The date of oral presentation will depend on the review schedule. Please prepare for presentation upon notification.

Selected Proposal will be notified in writing including the approved amount of funding by the **18th of August, 2020**.

➢ Conditions to Funding

The initial installment of funds will be disbursed by the Sponsors for the Selected Proposal following the execution of the Research Agreement which shall incorporate the terms substantially set forth in Exhibits B to D.

➢ Other Specifications

1. Proposals contemplated to be funded by the Sponsors need to be completed within thirty-six (36) months from the date of funding;

2. Applicant may not obtain any other funding to conduct the Selected Proposal without each Sponsor's consent.

3. Research funding provided herein should be used exclusively for the Selected Proposal (overhead/indirect costs must not exceed 10% of the total cost of Selected Proposal).

4. Except as otherwise provided in its Proposal and received by the Committee, Applicant may not engage any subcontractors or collaborators without each Sponsor's consent.

5. Applicant should obtain and maintain adequate insurance to cover any liability arising from its conduct of the Selected Proposal.

6. Each Sponsor may terminate the research program for any reason upon thirty (30) days' notice or immediately at any time if the Sponsors are not satisfied with the progress of the Selected Proposal, or if principal researcher was replaced without each Sponsor's consent.

7. Applicant shall be responsible for any costs and expenses arising from participating in the Event.

8. Proposals will be reviewed by the Committee at the Committee's sole discretion. Sponsors, their affiliates and their respective employees, agents, directors, officers, representatives, contractors, independent consultants, or any other associates, shall not be liable for any Applicant's remedies, damages, penalties, losses, expenses, fees, costs or liabilities of any kind or nature whatsoever, in connection with Applicant's participation in the Event, except to the extent required by applicable laws.

9. Any and all taxes, duties, levies, and fees imposed by any government authority in connection with this Event shall be borne by Applicant.

10. Applicant of Selected Proposal shall set up a separate account (the "Separate Account") to manage the use of all research funding. Applicant agrees to permit any authorized representative appointed by Sponsor(s) to carry out an audit of the Separate Account.

11. Applicant agrees to cooperate with ITRI to abide by all the applicable law of Ministry of Economic Affairs, or Ministry of Science and Technology of Republic of China (Taiwan).

12. Sponsors will need to collect, process, and use Applicant's personal information, including names, office address and other contact information, which may be provided to Sponsors' affiliates and their respective employees, agents, representatives, contractors, independent consultants, and other associates. Sponsors will comply with the provisions of the Personal Data Protection Act ("PDPA") Taiwan, where ITRI acts as a data controller in the processing of personal data in this Event.

13. Applicant is not required to accept terms and conditions on Exhibit B as a condition to applying for the research funding. However, Sponsors will consider whether an Applicant has given an affirmative confirmation when selecting Proposals.

14. In the event of the expiration of the term or any termination of the Research Agreement, all unused funds shall be promptly returned to the Sponsors.

15. The validity, construction, and performance of this Event is governed by the laws of the Republic of China (Taiwan). All claims brought by an Applicant against the Sponsors in connection with the Event or its subject matter that are not resolved by the Sponsors and Applicant through negotiations shall be submitted to the Hsinchu District Court of the Republic of China (Taiwan). For the avoidance of doubt, the terms of the Research Agreement shall govern all relevant disputes arising under such Research Agreement.

16. In the event any detail herein is modified, Sponsors should disclose it on the website https://jti.itri.org.tw/index.aspx, without further notice.

➢ Contact Information

Carol Chiu(邱小容)/Administrator
Industrial Technology Research Institute/ Janssen Taiwan Initiative Office
工業技術研究院/ JTI 計畫辦公室
TEL: 886+3+5913740
E-Mail：jtioffice@itri.org.tw
ADDRESS: Rm.135, Bldg.52, No. 195, Sec. 4, Chung Hsing Rd., Chutung, Hsinchu, Taiwan 31057, R.O.C.

Exhibit A

RESEARCH GRANT CO-FUNDING
HEALTHCARE COMPLIANCE DUE DILIGENCE QUESTIONNAIRE

These questions are designed to demonstrate J&J's compliance intentions regarding its Healthcare Compliance Policies and various potentially applicable laws and regulations.

For the purposes of this Questionnaire:

"Health Care Professionals" or "HCPs" *means:*

1. *All physicians;*
2. *Any other individual, institution or entity with the ability to prescribe, acquire or influence the prescription or acquisition of healthcare products or services at issue, and either of the following:*

    a. *The products at issue are regulated or registered as medicinal products or devices (or their equivalents) in the applicable country; or*
    b. *The products or services at issue are subject to reimbursement by government or third parties; or, are offered for sale with products or services subject to such.*

"Family Members" *means one of the following relationships: mother, father, spouse, civil union partner, sister, brother, son, daughter, grandchild, grandparent, any of the preceding who where applicable, are "step" relatives, mother-in-law, father-in-law, sister-in-law, brother-in-law, son-in-law, and daughter-in-law.*

Notes:

1. Please check the boxes for the appropriate answer where the option is provided, or provide the appropriate answer in the space provided.
2. 'You' in the questions below refer to （1）the applicant of this Research Grant Co-funding, or (2) the principal researcher of the proposal which will be submitted to the Event.
3. If there is insufficient space in the right column to provide your answers, please add additional pages as necessary.
4. For listed companies, 'shareholders' in the questions below refer to shareholders holding equal to or more than 10% of stocks or voting rights.

1. Are you participating in this Research Grant Co-funding as an employee of a government-linked entity or a corporate entity?	☐ Government-linked Entity. Please go to Section G. ☐ Corporate Entity. Please go to Section C.
SECTION G – For Participants from Government-linked Entities	

2. Which government-linked entity(ies) do you work for? Please list all.	Name of Government-linked Entity: Please go to 3a.
3a. Are you a HCP (Health Care Professional)?	☐ Yes. Please go to 3b. ☐ No. Please go to 4.
3b. If so, please provide the following details. **i. Is the HCP licensed or practicing?** **ii. Area of practice** **iii. Current affiliations (e.g., hospitals, universities, ACOs, formulary committees, procurement committees, product review committees, product advisory committees, Boards, etc.)** **iv. Do you have any influence on the use, recommendation, procurement or approval of J&J products?** **v. Do you have any prior or current relationships with J&J or any J&J subsidiary? (e.g., a paid speaker or consultant to any J&J products, engaged in J&J company sponsored research, engaged in a clinical study funded by a J&J Company, etc.)**	HCP License: ☐ Past ☐ Current Are you currently practicing as a HCP? ☐ Yes ☐ No Area of Practice: Current Affiliations: Do you have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Please go to 4.
4. Are you currently a customer of J&J products or services?	☐ Yes. Please go to 5a. ☐ No. Please go to 5a.
5a. Are any of your family members employees of J&J?	☐ Yes. Please go to 5b. ☐ No

5b. If 'Yes', please provide details.	Name: Relationship:
SECTION C – For Company Participants	

6a. Are there any owners (shareholders or partners) of your company or institution who are HCPs (Health Care Professionals)?	☐ Yes. Please go to6b. ☐ No. Please go to 7a.
6b. If so, please provide the names of these HCPs and details of their economic interest and position with your company. **i. Is the HCP licensed or practicing?** **ii. Area of practice** **iii. % ownership of company** **iv. Current affiliations (e.g., hospitals, universities, ACOs, formulary committees, procurement committees, product review committees, product advisory committees, Boards, etc.)** **v. Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products?**	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐ Yes ☐ No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No

vi. Does the HCP have any prior or current relationships with J&J or any J&J subsidiary? (e.g., a paid speaker or consultant to any J&J products, engaged in J&J company sponsored research, engaged in a clinical study funded by a J&J Company, etc.) vii. **Will the HCP be involved in this research proposal/project?**	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐ Yes ☐ No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No
	Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No Please go to 7a.
7a. Do any HCPs own options to obtain shares in your company?	☐ Yes. Please go to 7b. ☐ No. Please go to 8a.

7b. If so, please provide the names of these HCPs and details of their economic interest and position with your company. **i. Is the HCP licensed and practicing?** **ii. Area of practice** **iii. % ownership of company** **iv. Current affiliations (e.g., hospitals, universities, ACOs, formulary committees, procurement committees, product review committees, product advisory committees, Boards, etc.)** **v. Does the HCP have any prior or current relationships with J&J or any J&J subsidiary? (e.g., a paid speaker or consultant to any J&J products, engaged in J&J company sponsored research, engaged in a clinical study funded by a J&J Company, etc.)** **vi. Will the HCP be involved in this research proposal/project?**	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐ Yes ☐ No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No

	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐ Yes ☐ No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No Please go to 8a.
8a. Do any HCPs hold debt instruments in your company?	☐ Yes. Please go to 8b. ☐ No. Please go to 9a.

8b. If so, please provide the names of these HCPs and details of their economic interest and position with your company. **i. Is the HCP licensed and practicing?** **ii. Area of practice** **iii. % ownership of company** **iv. Current affiliations (e.g., hospitals, universities, ACOs, formulary committees, procurement committees, product review committees, product advisory committees, Boards, etc.)** **v. Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products?**	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐ Yes ☐ No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No

vi. Does the HCP have any prior or current relationships with J&J or any J&J subsidiary? (e.g., a paid speaker or consultant to any J&J products, engaged in J&J company sponsored research, engaged in a clinical study funded by a J&J Company, etc.) **vii. Will the HCP be involved in this research proposal/project?**	Name: Position in Company: HCP License: ☐ Past ☐ Current Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No Please go to 9a.
9a. Are any key personnel (Board members, Officers of the Company, key employees) an HCP?	☐ Yes. Please go to 9b. ☐ No. Please go to 10a.

9b. If so, please provide the names of these HCPs and details of their economic interest and position with your company. **i. Is the HCP licensed and practicing?** **ii. Area of practice** **iii. % ownership of company** **iv. Current affiliations (e.g., hospitals, universities, ACOs, formulary committees, procurement committees, product review committees, product advisory committees, Boards, etc.)** **v. Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products?**	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐ Yes ☐ No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No

vi. Does the HCP have any prior or current relationships with J&J or any J&J subsidiary? (e.g., a paid speaker or consultant to any J&J products, engaged in J&J company sponsored research, engaged in a clinical study funded by a J&J Company, etc.) **vii. Will the HCP be involved in this research proposal/project?**	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐ Yes ☐ No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No Please go to 10a.
10a. Are your company owners, partners, shareholders, or key decision makers a Government Official or affiliated with a Government Official?	☐ Yes. Please go to 10b. ☐ No. Please go to 11a.
10b. If 'Yes', please provide name(s) and the individual's(s') position(s).	Name: Position: Government Institution/Agency:
	Name: Position: Government Institution/Agency: Please go to 11a.

11a. Are your company owners, partners, shareholders, key decision makers currently working for a government-owned or a government-linked institution (e.g., a public hospital) which is or could potentially be a J&J customer? Note: This includes providing advisory, consulting or part-time services.	☐ Yes. Please go to 11b. ☐ No. Please go to 12a.
11b. If 'Yes", please provide name of the government-owned or government-linked institution(s).	Please go to 12a.
12a. Are any of the family members of the owners, principals, or board members of your company or your parent company employees of J&J?	☐ Yes. Please go to 12b. ☐ No
12b. If 'Yes', please provide details.	Name: Relationship:

COMPLETED BY	
Signature	
Name	
Date	

Exhibit B

Terms Sheet for Research Agreement and License Option

This term sheet (the "**Term Sheet**") sets forth the basic terms and conditions of the Research Agreement that the applicant ("**you**" or "**Institution**") will be required to agree to with Janssen Biotech, Inc. ("**JBI**") or its affiliate (excluding JBI's affiliates in the People's Republic of China), and/or Industrial Technology Research Institute ("**ITRI**") (together, the "**Sponsors**") and execute as a condition to receiving research funding for the proposed research program.

Please review the basic terms and conditions of the Research Agreement detailed below. By signing the acknowledgement at the end of this Term Sheet, you are indicating that you accept the terms and conditions contained herein, subject to their incorporation together with all other terms and conditions in the Research Agreement. You also acknowledge that this Term Sheet does not contain all the terms and conditions to be included in the Research Agreement and the Sponsors reserve the right to include additional terms and conditions not specified herein in the Research Agreement.

For clarity, you are not required to acknowledge your agreement to the terms and conditions set forth in this Term Sheet as a condition to applying for the research funding. However, the Sponsors will consider whether you have acknowledged and agreed to the terms and conditions set forth in this Term Sheet when selecting potential candidates to receive research funding.

Parties	• JBI or its affiliate (excluding JBI's affiliates in the People's Republic of China) • ITRI • Applicant ("**Institution**")
Research Program	• Institution will conduct the research in accordance with the timelines, milestones, and deliverables set forth in the mutually agreed upon research program. • The parties will establish a joint steering committee, with equal membership from each party, to monitor the progress of the research program, to review research results, and to modify the research program by unanimous decision. • Research funding will be provided in accordance with an agreed-upon budget and payment schedule and will be used exclusively for the research.

	• Institution may not obtain any other funding to conduct the research without each Sponsor's consent. • Except as otherwise provided in its proposals received by selection committee, Institution may not engage any subcontractors or collaborators without each Sponsor's consent. • Institution will obtain and maintain adequate insurance to cover any liability arising from its conduct of the research. • Each Sponsor may terminate the research program for any reason upon thirty (30) days' notice or immediately at any time if the Sponsors are not satisfied with the progress of the research.
Principal Investigator	• Institution will designate a principal investigator to conduct and directly supervise the research program. • Each Sponsor may terminate the research program in the event the principal investigator ceases to be involved in the research program or Institution is unable to find a replacement principal investigator acceptable to each Sponsor.
Research Agreement	
Ownership of Program Technology	• For the avoidance of doubt, JBI does not intend to contribute any technology to Institution to conduct research, provided however, in the event that there is any dispute with regard to whether JBI has contributed technology to a particular Institution or research program, such dispute shall be resolved by binding arbitration pursuant to the Governing Law/Dispute Resolution section below. • Ownership of all technology developed under the research program shall be determined based on inventorship, and for all other technology which inventorship does not apply, will be owned by Institution, except, if JBI provides any technology to Institution to conduct the research, JBI will own any technology that uses, is based on, or is an improvement to any JBI technology (regardless of inventorship, including such technology jointly developed by Institution and JBI, or developed solely by Institution). • Inventorship for purposes of the Research Agreement shall be determined in accordance with United States patent law.

Research License	• Institution grants to JBI a non-exclusive, worldwide, royalty-free, non-transferable, perpetual license under the program technology and related products owned by Institution (the "**Licensed Technology**") to make and use Licensed Technology solely for JBI's internal research or educational purposes (which may include research performed with one or more third party collaborators) (excluding the use of any Licensed Technology in clinical studies and in research sponsored by a business or for-profit entity (or an affiliate of a business or for-profit entity)) and to have any of the foregoing performed on JBI's behalf by a third party service Applicant.
JBI Right of First Negotiation and Trailing Right of First Refusal	• At the conclusion or termination of the research program, Institution will in good faith provide to JBI a data package containing sufficient information to enable JBI to (i) determine whether to exercise its right of first negotiation and (ii) negotiate for itself or its designee or assignee an exclusive, worldwide license to the Licensed Technology (the "**Data Package**"). Institution further agrees that it shall provide any supplemental information requested by JBI to facilitate JBI's determination on whether to exercise its right of first negotiation and to negotiate for itself or its designee or assignee the License. • Right of First Negotiation. Institution grants to JBI, for a period starting from the effective date of the Research Agreement and continuing until the day that is sixty (60) days following the delivery of the Data Package ("**ROFN Exercise Period**"), the exclusive option to negotiate for itself or its designee or assignee an exclusive, worldwide license to the Licensed Technology upon the terms set forth in the License section below ("**License**") (such option, the "**JBI Option**"). For the avoidance of doubt, the Institution and JBI acknowledge and agree that the terms set forth in the License section below are non-negotiable and any negotiations relating to the definitive License shall be limited to those matters not set forth below (subject to written waiver by JBI). In the event JBI exercises the JBI Option during the ROFN Exercise Period by delivery of written notice to Institution ("**Exercise Notice**"), Institution shall negotiate in good faith and exclusively with JBI and/or one or more affiliates of JBI for any such affiliate for a period of one hundred and eighty (180) days from the date of the Exercise

	Notice (the "**Exclusive Negotiation Period**") to enter into a License with the Institution. o From the effective date of the Research Agreement and until the expiration of the Exclusive Negotiation Period has ended, Institution may not (i) transfer any Licensed Technology to a third party, (ii) solicit, initiate, continue or engage in any negotiations or discussions (nor disclose or furnish to any other party any information concerning your assets or business in contemplation of a Transaction) relating to Licensed Technology, or consider or respond to any indication of interest, offer or proposal, to enter into any agreement or understanding to consummate a Transaction relating to Licensed Technology, or (iii) enter into any Transaction with a third party relating to Licensed Technology without the prior written consent of JBI. o "Transaction" shall mean any transaction (i) which would sell, license, transfer, assign or otherwise make available (A) any Rights in or to any of Institution's significant assets or a significant portion of Institution's assets (including, without limitation, any of the Rights (as defined below)) or (B) any of Institution's capital stock or other equity interest or (ii) which would involve any business combination or merger, in either case, involving Institution or any of Institution's Affiliates in their capacities as such. The term "Rights" shall include all inventions, developments, patents, patent applications, know-how or other proprietary rights or products owned, developed or acquired (whether through license or otherwise) by the Institution related to Licensed Technology. • Right of Last Refusal. For a period of one hundred twenty (120) calendar days following the expiration of the Exclusive Negotiation Period (the "**Tail Period**" and, the last date of such period, the "**Expiration Date**"), the Institution shall not consummate or agree to consummate a Transaction with any other party (a "**Third Party**") without first giving prompt notice

	thereof to JBI in writing (the "**Proposed Transaction Notice**") (i) specifying the pricing, terms, conditions and other material provisions of such proposed Transaction, (ii) identifying the proposed Third Party and (iii) providing a copy of a written agreement in principal or letter of intent setting forth the terms of such proposed Transaction, if any such written agreement or letter of intent exists. In the event that JBI elects to consummate a transaction upon the same pricing, terms, conditions and other material provisions as specified in the Proposed Transaction Notice, JBI shall have thirty (30) calendar days to so notify Institution and Institution shall use all reasonable commercial efforts to facilitate the consummation of such Transaction with JBI and/or its affiliates within sixty (60) calendar days following the receipt of such notification (such sixty (60) day period, the "**Negotiation Period**"). Notwithstanding the foregoing, upon the Expiration Date all rights relating to this Right of Last Refusal shall terminate and any Proposed Transaction Notice period or Negotiation Period, together with all rights to receive Notices, to cause a Negotiation Period to occur and to receive any additional Proposed Transaction Notices based on changes in transaction terms, shall terminate upon the Expiration Date. • The Parties hereby acknowledge and agree that the Parties shall have no obligation (in each party's sole discretion) to enter into a definitive agreement concerning a Transaction. Institution hereby represents and warrants to JBI that the granting of the Right of First Negotiation, Right of Last Refusal and other terms provided herein will not conflict with or infringe upon the rights of any other person or entity.
Termination	• In the event of the expiration of the term or any termination of the Research Agreement, all unused funds shall be promptly returned to the Sponsors.
Governing Law/Dispute Resolution	• The Research Agreement will be governed by the laws of the State of New York. • The parties will resolve any disputes arising from the Research Agreement via arbitration in Hong Kong according to the rules of the Hong Kong International Arbitration Center.
License	

	• Institution will grant to JBI an exclusive, worldwide, royalty-bearing, sub-licensable license under the Licensed Technology to develop, manufacture, and commercialize the Licensed Technology and related products in any field. • JBI and Institution will each appoint an alliance manager to be the point of contact and to coordinate between the parties.
Development and Commercialization	• JBI will, in its sole discretion, determine whether to develop and commercialize the Licensed Technology and related products. • JBI will be solely responsible for all decisions regarding the development, manufacturing, and commercialization of the Licensed Technology and related products. • JBI will pay to Institution certain milestones and royalties as determined by the Parties following JBI's exercise of the JBI Option, subject to customary royalty-reductions for generic entry, loss of patent rights, and third-party obligations. • The royalty term will terminate, on a product-by-product and country-by-country basis, upon the earliest of (i) the expiration of the latest to expire of Institution's patents covering the Licensed Technology, (ii) the expiration of any data exclusivity, or (iii) 10 years after the first commercial sale of a related product. • Institution will have customary audit rights. • Institution will provide customary representations and warranties regarding the Licensed Technology, including non-infringement.
Ownership of Technology Developed Under the Exclusive License	• JBI will own any technology and intellectual property developed in connection with the development, manufacturing, and commercialization of the Licensed Technology and related products and will be solely responsible for filing, prosecuting, and maintaining any patent rights.
Governing Law/Dispute Resolution	• The License will be governed by the laws of the State of New York. • The parties will resolve any disputes arising from the License via arbitration in Hong Kong according to the rules of the Hong Kong International Arbitration Center.

ACKNOWLEDGED AND AGREED

By: _____

Name:

Organization:

Title:

Exhibit C

Statement Against Corrupt Practices

Compliance with Anti-Corruption Laws

Notwithstanding anything to the contrary in the Research Agreement, Applicant hereby agrees that:

(i) Applicant has not and shall not perform any actions that are prohibited by local and other anti-corruption laws (collectively "Anti-Corruption Laws") that may be applicable all parties to the Research Agreement;

(ii) Applicant has not and shall not, directly or indirectly, make any payment, or offer or transfer anything of value, or agree or promise to make any payment or offer or transfer anything of value, to a government official or government employee, to any political party or any candidate for political office or to any other third party related to the transaction with the purpose of influencing decisions related to Johnson & Johnson (the "Company"), its affiliates and/or its business in a manner that would violate Anti-Corruption Laws;

(iii) Applicant has not and shall not retain any government official or government employee in the performance of the Research Agreement unless it has been approved by Company and, if necessary, by the competent authority or authorities and such government official's or employee's employer. Furthermore, Applicant shall immediately advise Company in writing in the event Applicant becomes aware that any person engaged in the performance of the Research Agreement becomes a government official or employee, a political party official or a candidate for political office. The requirements of this subsection shall not apply with respect to employees of an Applicant that is a government owned entity;

(iv) Applicant shall designate an individual within its organization to receive training from Company on Anti-Corruption Laws as well as applicable rules on interactions with health care professionals, as mutually agreed to by the parties. Such designated individual shall then provide such training on Anti-Corruption Laws, using applicable training materials to be provided by Company, on at least an annual basis to all persons employed by Applicant who perform work in connection with the Company and interact with government officials or health care professionals in the normal course of their responsibilities. Upon Company's and Applicant's mutual agreement, such training may also be provided directly by Company to such employees of Applicant. Applicant shall also provide such training or training materials to any subcontractors it uses in the performance of the Research Agreement (to the extent the use of such subcontractors by Intermediary is permitted under the Research Agreement.) Any

training and materials provided by Company does not relieve Applicant of any obligations it has independent of the Research Agreement and Applicant shall not rely on Company's training and materials for any such obligations;

(v) Applicant shall certify on an annual basis in a format to be provided by Company that:

a. training and training materials on Anti-Corruption Laws as well as applicable rules on interactions with health care professionals, have been provided to all persons employed by Applicant who perform work for Company and interact with government officials or health care professionals in the normal course of their responsibilities and that it has provided the Company training and training materials to subcontractors used by Applicant in the performance of the Research Agreement;

b. to the best of Applicant's knowledge, there have been no violations of Anti-Corruption Laws by Applicant or persons employed by or subcontractors used by Applicant in the performance of the Research Agreement;

c. personnel of Applicant who may be designated as "Key Personnel" by mutual agreement of Company and Applicant have not changed, except as noted in a schedule attached to the certification provided by Applicant;

d. Applicant has made no changes in its use of subcontractors to perform the services for the Company under the Research Agreement, except as (1) permitted under the Research Agreement and (2) noted in a schedule attached to the certification provided by Applicant; and

e. Applicant has maintained true and accurate records necessary to demonstrate compliance with the requirements of this Exhibit.

(vi) Applicant shall maintain and provide Company and its auditors and other representatives with access to records (financial and otherwise) and supporting documentation related to the subject matter of the Research Agreement as may be requested by Company in order to document or verify compliance with the provisions of this Exhibit; and

(vii) if Applicant fails to comply with any of the provisions of this Exhibit, such failure shall be deemed to be a material breach of the Research Agreement and, upon any such failure, Company shall have the right to terminate the Research Agreement with immediate effect upon written notice to Applicant without Company having any financial liability or other liability of any nature whatsoever resulting from any such termination.

ACKNOWLEDGED AND AGREED

By: _____

Name:

Organization:

Title:

Exhibit D

Statement of Compliance with Federal Animal Welfare Regulations

Notwithstanding anything to the contrary in the Research Agreement, Applicant hereby agrees that:

In the event of a necessary relocation, Applicant must immediately contact JRD.

The Applicant represents and warrants that the procurement, delivery, preparation, supply, housing, care, and disposition of animals or animal tissues used for the purposes stated in the Research Agreement shall be in compliance with all applicable laws, regulations, governmental guidelines, and industry standards with respect to laboratory animal welfare and safeguarding of animal welfare, such as, but not limited to (i) the United States Animal Welfare Act, (ii) the rules and regulations of the National Institutes of Health (NIH), U.S. Department of Agriculture (USDA), or other governmental agencies; (iii) any guidelines, rules and regulations of the European Union and its national regulations; (iv) the Regulations for the Administration of Affairs Concerning Experimental Animals of the country in which Applicant locates and other applicable laws, regulations or governmental guidelines thereof , or (v) the law of any other jurisdiction as may apply.

Applicant shall be the owner of any animals used hereunder at all times and it shall obtain the approval/license/certificate for all activities involving animals from the appropriate Ethics Committee or regulatory authority. Ethics Committee shall mean the ethical committee responsible for overseeing animal care and use, which may include, but is not limited to, the Institutional Animal Care and Use Committee (IACUC) for US companies, an Ethics Committee on Animal Experiments (ECAE), and/or Animal Welfare Body for European companies.

Applicant shall not initiate any activity involving live animals unless the protocol used for the activity has been reviewed and approved by Applicant's Ethics Committee. A copy of such approval decision shall be provided to Janssen upon request.

When live animals are to be used in conjunction with the activity, the Applicant agrees to treat such animals humanely and use only humane and appropriate methods of euthanasia such as those described in the American Veterinary Medical Association (AVMA) guidelines on euthanasia, those established under the EU legislation on the protection of animals used for scientific purposes, or those established under the laws of any other jurisdiction as may apply. The Applicant's failure to abide by these requirements in connection with the delivery of animal related service shall be deemed a material breach and be grounds for Janssen's termination of this agreement.

Applicant represents and warrants that it understands that the Janssen expects its external service Applicants to follow the same standards as described in the J&J Policy on The Humane Care & Use of Animals, which is included in Attachment 1 attached.

If Applicant is AAALAC accredited.

Applicant represents and warrants that the facility where the activities involving animals are being conducted is

AAALAC accredited. Applicant shall maintain its accredited status for the facilities listed within the agreement for the duration of the Research Agreement. Applicant shall immediately notify Janssen if a facility's AAALAC accreditation is not continuously maintained for any reason. Janssen (or Janssen's authorized representative) may inspect the facility where the activities involving animals are being conducted and review Applicant's animal care and use program. Applicant will cooperate with Janssen (or Janssen's authorized representative) during inspection and review.

If Applicant is not AAALAC accredited.

If the facility where the activities involving live animals are intended to be conducted is not currently accredited by AAALAC, Applicant will permit Janssen (or Janssen's authorized representative) access to the facility where the activities are intended to be conducted in order to evaluate the Applicant's animal care and use program. Applicant will cooperate with Janssen (or Janssen's authorized representative) during the evaluation and review.

Reporting

The Applicant agrees to provide a report with animal usage information to Janssen as requested, but no less than once annually. Such report should include all live animals which have been entered into the respective study(ies)/activities in the prior year, and at a minimum will contain at least the name and reference number of the protocol, animal species, number of animals used, start and end date, and the Applicant's contact person. An example of the reporting document is included in Attachment 2 attached. Additional information may be requested as agreed upon by the parties.

ACKNOWLEDGED AND AGREED

By: _____

Name:

Organization:

Title:

ATTACHMENT 1

Johnson & Johnson

Policy on the Humane Care & Use of Animals

Johnson & Johnson have a responsibility to ensure the ethical and humane treatment of animals that are used to

advance patient safety and well-being. The care and use of laboratory animals in biomedical procedures is highly regulated. In general, the regulations govern procurement, housing, feeding, veterinary care, research project review, and require both internal and external inspections. Our companies have clear, well-developed policies and guidelines in place that mandate and drive the ethical and humane treatment of the animals we use, and that promote the use of non-animal alternatives whenever possible. We support and participate in efforts to obtain regulatory acceptance of any alternative testing methods. Our standards for animal care and use meet or exceed all applicable local, state and national laws and regulations.

Our corporation is committed to the "3R" Principles

•• Replacement –Using alternative non-animal systems in place of live animal utilization whenever possible
•• Reduction – Using the minimum number of animals possible to achieve maximum information without compromising animal welfare
•• Refinement – Continually modifying procedures to limit the discomfort and distress to animals

Institutional Animal Care and Use Committee (IACUC)/Ethical Review

•• Proposed Animal studies must be reviewed and approved by an IACUC or equivalent
Ethical Committee.

Personnel Training – Competency

•• Personnel involved with the care and use of animals must be educated, trained, and/or qualified in the principles of animal welfare and compliance to help ensure quality science and animal well-being.

Sourcing Animals & Tissue

•• Live animals, preferably bred and raised specifically for research, and animal tissue used in research and teaching shall be obtained only from appropriate sources.

•• Euthanasia: Only humane and appropriate methods of euthanasia will be used, such as those described in the American Veterinary Medical Association (AVMA) guidelines on euthanasia and those established under the EU legislation on the protection of animals used for scientific purposes.

Teaching & Education

•• Live animals shall only be used when actual participation by the trainee is required to learn a medical or surgical procedure (including proper product usage) where alternate models have been deemed inadequate for the purpose.
•• We are committed to continually seek ways to refine training requirements that yield additional reductions in the use of animals in testing.

Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC)

•• We require that all Johnson & Johnson Animal facilities be AAALAC accredited.

•• Newly acquired non-accredited companies are expected to apply for accreditation

External Service Applicants

•• Johnson & Johnson expects the standards for animal care & use for external service Applicants to follow the same standards as described in this document.

◊ Standards for animal care and use will meet or exceed all applicable local, state and national laws and regulations.

◊ Johnson & Johnson preference is to work with external service Applicants that are AAALAC accredited. In cases where non-accredited external service Applicant use is justified, established Johnson & Johnson procedures must be followed and complied with to assure that such facilities meet Johnson & Johnson standards.

Cosmetics

•• The Johnson & Johnson Family of Consumer Companies does not test cosmetic products or ingredients on animals and we do not ask others to test on our behalf, except in those cases where testing is required by law or government regulations.

ATTACHMENT 2

Institution/CRO Name, Location, Country	Contractor's Contact	J&J Op CO	J&J Contact	Protocol / Study ID	Protocol / Study Title	Species	# of Animals	Study / Activity Start date	Study / Activity Term date

Exhibit E

Notification and Consent Regarding Collection, Processing and Use of Personal Information

Notification

In order to collect, process, and use your personal information which you have provided or will provide (hereinafter referred to as "the Personal Information"), based on the reason that you are participating in "ITRI 2020 Grant Call in Collaboration with Janssen", SPONSORS would like to inform you about the following matters:

A. Purposes for collection: Industry-Academy Cooperation Management

B. Classification of the Personal Information: Type for identifying individuals, (For the principal researcher of the Proposal which will be submitted to the Event, "details about your other family members", and "Professional and Technical Personnel Management" may be needed according to Exhibit A.)

C. Time period of the use of the Personal Information: until the purposes for collecting the information no longer exists.

D. Areas of use of the Personal Information: The territory of the ROC and SPONSORS's overseas locations and offices.

E. Users of the Personal Information: SPONSORS as well as government agencies and non-government agencies that have or will have business relations with SPONSORS.

F. Way of the use of the Personal Information: Under the condition that there is no excess of the scope of the purposes for which the Personal Information was collected, the Personal Information may be used on the Internet, in e-mail, in documents, in facsimiles, and in other lawful ways.

G. You may exercise the following rights by raising written request(s):

1. any inquiry and request for a review of the Personal Information;
2. any request to make duplications of the Personal Information;
3. any request to supplement or correct the Personal Information;
4. any request to discontinue collection, processing or use of the Personal Information; and
5. any request to delete the Personal Information.

H. If you do not sign this Notification and Consent Regarding Collection, Processing and Use of Personal Information, SPONSORS may not be able to contact with you.

I. SPONSORS will keep your Personal Information confidential and in proper custody in accordance with the relevant laws and regulations of the ROC.

Consent

I have read and understood the Notification set forth above, and hereby agree that SPONSORS may, within the scope of and in conformity with the contents of said Notification, collect, process and use the Personal Information. This consent may be expressed in the way of an electronic document.

The Party: _____

Name :

Address :

ID Number :

Date :

➢ 徵案標的

徵求國內生醫領域符合參加資格之提案團隊提出研究計畫，研究計畫應為下列領域，且提出以解決下列任一重要問題為目標之可能方案（下稱：徵案標的）：

標的領域：

1. 肺癌及其人工智慧之應用(Lung Cancer /AI)
2. 傳染性疾病預防(Infectious Diseases)
3. 小兒疾病的偵測、診斷及預防(Healthy Baby / Big Data)
4. 成人疾病預防及其人工智慧與大數據之應用(Disease Prevention / Big Data / AI)

優先探討之重要方向：

1. 肺癌及其人工智慧之應用(Lung Cancer /AI)
   - ➢ 如何以非慣行方法（目前為 CT 醫療影像）更早地辨識出肺癌患者？
   - ➢ 如何辨識肺癌高危險群，以及如何讓他們受到保護？
   - ➢ 如何運用虛擬實境或遊戲化等數位療法，減少有吸煙習慣的肺癌患者？
2. 傳染性疾病預防(Infectious Diseases)
   - ➢ 可長效預防病毒性呼吸道感染疾病的新型非疫苗技術（針對病毒或宿主）為何？
3. 小兒疾病的偵測、診斷及預防(Healthy Baby / Big Data)
   - ➢ 如何事先預測嬰兒會罹患哪些早期生命疾病，例如異位性皮膚炎、哮喘及過敏等。
   - ➢ 哪些新型非侵入性的儀器設備可以用來幫助嬰兒檢測及監測疾病？
   - ➢ 幫助嬰兒發育的營養方法為何？
4. 成人疾病預防及其人工智慧與大數據之應用(Disease Prevention / Big Data / AI)
   - ➢ 可用於檢測成人健康狀況變化的非侵入性的儀器設備為何？
   - ➢ 穿戴式設備和傳感器如何監測成年人的健康？
   - ➢ 哪種類型的家庭診斷方式可被用來監測成人或家庭的健康狀況？
   - ➢ 整體而言大數據如何應用於疾病的事前診斷？

➢ 提案方式

提案團隊請於徵案時間截止日至 **2020 年 5 月 14 日**下午 5 時整（含）前發送電子郵件至 jtioffice@itri.org.tw 信箱（請於電子郵件主旨上註明「Janssen-Taiwan 合作計畫：20120 研究案徵求公告」，並請於電子郵件內文中陳明：提案團隊所屬單位名稱、計畫名稱、聯絡方式、計畫主持人姓名、職稱），上傳提案文件予聯絡人。

提案文件：

1. 提案團隊計畫主持人簡歷；
2. 提案技術發展狀況（計畫書）；
3. 非機密之摘要、說明、與關鍵字；
4. 提案之應用及/或與徵案標的之相關性；
5. 提案預算（包含管理費用/間接費用）、提案團隊的投入、查核點；
6. 填寫完成附件 A 的 research grant co-funding healthcare compliance due diligence questionnaire；
7. 提案團隊是否同意依附件 B 之內容簽署研究契約之確認書（為免疑義，特別說明，即使填寫不同意附件 B 之內容，提案計畫仍可以參加徵選）
8. 簽署如附件 C 的 Statement Against Corrupt Practices；
9. 簽署如附件 D 的 Statement of Compliance with Federal Animal Welfare Regulations；
10. 提案團隊的每位成員均簽署如附件 E 的"Notification and Consent Regarding Collection, Processing and Use of Personal Information"；
11. 提案團隊與 Janssen 或其關係企業（包括任何 J & J 公司關係企業）的競爭對手沒有實質的關聯性之聲明。

➢ 評選方式

1. 主辦單位將指派人選組成評選委員會。評選委員會將就提案團隊資格、提案文件進行綜合審查評比。審查標準請詳見 https://jti.itri.org.tw/index.aspx 網站「提案申請」項下「其他參考資料」的「申請說明」（"Application Instructions"）。

2. 進入決選的提案團隊，委員會將請提案團隊就提案規劃進行簡報說明。屆時請提案團隊備妥簡報電子檔及書面文件。（簡報日期視審查進度，由委員會個別通知提案團隊。）

3. 每件獲選提案所取得之研究經費將由評選委員會於評選決議中核定，並以正式公函通知獲選團隊。

➢ 經費取得

1. 在獲選團隊收到獲選通知後 120 日內，應與工研院及 Janssen 簽訂研究契約（以下稱：研究契約）。
2. 承上，獲選團隊若是企業或經濟部下轄的法人，除於前述期間內與工研院及 Janssen 簽訂研究契約外，獲選團隊並需配合主辦單位將提案計畫另送經濟部審核通過。
3. 獲選團隊應簽訂附件 B (研究及優先選擇權授權契約重要條款)。
4. 獲選團隊應簽訂附件 C (廉潔保證文件)。
5. 獲選團隊應簽訂附件 D (符合聯邦動物福利法規的聲明)。

6. 簽署以上全部文件後，主辦單位將撥付第一期研究經費。

➢ Other Specifications

1. 提案計畫之全程，請勿超過 36 個月。
2. 提案團隊應自行負擔參加本徵案計畫全程之所有費用與支出。
3. 提案計畫獲選與否，由評選委員會依其考量全權決定。主辦單位及其代表人、代理人、受雇人、外聘顧問、或其他輔助人，均不因提案團隊參與本徵案計畫所受之損害或所失之利益負擔任何責任。
4. 提案計畫獲選與否，並不以提案團隊接受附件 B 的智慧財產議約條件為必要，但評選委員會將考慮提案團隊是否接受附件 B 的條件，作為評選考量之一。
5. 獲選計畫所簽訂之計畫內容不得申請、爭取、或接受其他來源之經費。
6. 獲選計畫所取得之研究經費，應全額用於執行獲選計畫（管理費用/間接費用不超過 10%）。
7. 獲選團隊因參與本徵案計畫相關的任何政府所課徵的所有稅捐，以及獲選計畫取得之研究經費所衍生之稅捐，均由獲選團隊自行負擔。
8. 獲選團隊就補助經費應設獨立帳戶專帳管理，並同意主辦單位所指定之代表就該獨立帳戶進行查核。
9. 除非提案計畫書已經載明，並獲得評選委員會之同意，獲選團隊不能將獲選計畫之全部或一部轉包、分包第三人，或以其內容與第三人合作研究。
10. 獲選團隊應配合工研院遵守所有中華民國行政院經濟部與科技部所制訂之相關法規。
11. 獲選計畫應就研究計畫自行投保適當之保險，以承擔執行本計畫所發生的任何損失。
12. 主辦單位若認為獲選計畫之執行不如預期，或獲選計畫未經同意中途更換計畫主持人，任一主辦單位得不附理由通知獲選團隊終止研究契約。
13. 因主辦單位應收集與處理提案團隊的個人資料，包含姓名、地址、及其他聯繫資訊；這些資訊將被提供給主辦單位的受雇人、代理人、代表人、外部顧問等。主辦單位同意將依照中華民國個人資料保護法所訂定的規範在本徵案計畫中處理、使用個人資料。
14. 研究契約終止或期間屆滿，未使用之研究費用應返還主辦單位。
15. 主辦單位保有本聯合徵案計畫相關細則變更之權力，設若有任何更動，皆以本聯合徵案計畫所屬網站 https://jti.itri.org.tw/index.aspx 公告為準，不再另行通知。
16. 本徵案計畫之準據法依中華民國法律。與本徵案計畫相關之訴訟，或經協商仍不能解決之爭議，將以台灣新竹地方法院為管轄法院。至於將來獲選計畫所簽訂之研究契約所衍生之爭議，其準據法與管轄法院，將依研究契約之約定。

➢ 聯絡方式

如有任何疑問，請向主辦單位聯絡窗口詢問，如下：

聯絡人： 邱小容

工業技術研究院/ Janssen Taiwan Initiative 計畫辦公室
電話：（03）591-3740
E-Mail：jtioffice@itri.org.tw
地址：新竹縣竹東鎮中興路 4 段 195 號 52 館 135 室

註：本公告中文版僅為方便提案團隊使用需求而提供。若中文公告文義與英文公告有不一致之處，以英文公告為準。

附件 A

RESEARCH GRANT CO-FUNDING
HEALTHCARE COMPLIANCE DUE DILIGENCE QUESTIONNAIRE

These questions are designed to demonstrate J&J's compliance intentions regarding its Healthcare Compliance Policies and various potentially applicable laws and regulations.

For the purposes of this Questionnaire:

"Health Care Professionals" or "HCPs" *means:*

1. *All physicians;*
2. *Any other individual, institution or entity with the ability to prescribe, acquire or influence the prescription or acquisition of healthcare products or services at issue, and either of the following:*

    a. *The products at issue are regulated or registered as medicinal products or devices (or their equivalents) in the applicable country; or*
    b. *The products or services at issue are subject to reimbursement by government or third parties; or, are offered for sale with products or services subject to such.*

"Family Members" *means one of the following relationships: mother, father, spouse, civil union partner, sister, brother, son, daughter, grandchild, grandparent, any of the preceding who where applicable, are "step" relatives, mother-in-law, father-in-law, sister-in-law, brother-in-law, son-in-law, and daughter-in-law.*

Notes:

1. Please check the boxes for the appropriate answer where the option is provided, or provide the appropriate answer in the space provided.
2. 'You' in the questions below refer to（1）the applicant of this Research Grant Co-funding, or (2) the principal researcher of the proposal which will be submitted to the Event.
3. If there is insufficient space in the right column to provide your answers, please add additional pages as necessary.
4. For listed companies, 'shareholders' in the questions below refer to shareholders holding equal to or more than 10% of stocks or voting rights.

1. Are you participating in this Research Grant Co-funding as an employee of a government-linked entity or a corporate entity?	☐Government-linked Entity. Please go to Section G. ☐Corporate Entity. Please go to Section C.
SECTION G – For Participants from Government-linked Entities	

2. Which government-linked entity(ies) do you work for? Please list all.	Name of Government-linked Entity: Please go to 3a.
3a. Are you a HCP (Health Care Professional)?	☐ Yes. Please go to 3b. ☐ No. Please go to 4.
3b. If so, please provide the following details. **i. Is the HCP licensed or practicing?** **ii. Area of practice** **iii. Current affiliations (e.g., hospitals, universities, ACOs, formulary committees, procurement committees, product review committees, product advisory committees, Boards, etc.)** iv. Do you have any influence on the use, recommendation, procurement or approval of J&J products? **v. Do you have any prior or current relationships with J&J or any J&J subsidiary? (e.g., a paid speaker or consultant to any J&J products, engaged in J&J company sponsored research, engaged in a clinical study funded by a J&J Company, etc.)**	HCP License: ☐ Past ☐ Current Are you currently practicing as a HCP? ☐Yes ☐No Area of Practice: Current Affiliations: Do you have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Please go to 4.
4. Are you currently a customer of J&J products or services?	☐ Yes. Please go to 5a. ☐ No. Please go to 5a.
5a. Are any of your family members employees of J&J?	☐ Yes. Please go to 5b. ☐ No
5b. If 'Yes', please provide details.	Name: Relationship:
SECTION C – For Company Participants	

6a. Are there any owners (shareholders or partners) of your company or institution who are HCPs (Health Care Professionals)?	☐Yes. Please go to6b. ☐No. Please go to 7a.
6b. If so, please provide the names of these HCPs and details of their economic interest and position with your company. **i. Is the HCP licensed or practicing?** **ii. Area of practice** **iii. % ownership of company** **iv. Current affiliations (e.g., hospitals, universities, ACOs, formulary committees, procurement committees, product review committees, product advisory committees, Boards, etc.)** v. Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? **vi. Does the HCP have any prior or current relationships with J&J or any J&J subsidiary? (e.g., a paid speaker or consultant to any J&J products, engaged in J&J company sponsored research, engaged in a clinical study funded by a J&J Company, etc.)** vii. Will the HCP be involved in this research proposal/project?	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐ Yes ☐ No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐Yes. Please provide details. ☐No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No
	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐Yes ☐No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No

	Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐Yes ☐No Please go to 7a.
7a. Do any HCPs own options to obtain shares in your company?	☐Yes. Please go to 7b. ☐No. Please go to 8a.
7b. If so, please provide the names of these HCPs and details of their economic interest and position with your company. **i. Is the HCP licensed and practicing?** **ii. Area of practice** **iii. % ownership of company** **iv. Current affiliations (e.g., hospitals, universities, ACOs, formulary committees, procurement committees, product review committees, product advisory committees, Boards, etc.)** **v. Does the HCP have any prior or current relationships with J&J or any J&J subsidiary? (e.g., a paid speaker or consultant to any J&J products, engaged in J&J company sponsored research, engaged in a clinical study funded by a J&J Company, etc.)** vi. Will the HCP be involved in this research proposal/project?	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐ Yes ☐ No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No

	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐ Yes ☐ No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No Please go to 8a.
8a. Do any HCPs hold debt instruments in your company?	☐ Yes. Please go to 8b. ☐ No. Please go to 9a.

8b. If so, please provide the names of these HCPs and details of their economic interest and position with your company. **i. Is the HCP licensed and practicing?** **ii. Area of practice** **iii. % ownership of company** **iv. Current affiliations (e.g., hospitals, universities, ACOs, formulary committees, procurement committees, product review committees, product advisory committees, Boards, etc.)** v. Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products?	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐ Yes ☐ No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No

vi. **Does the HCP have any prior or current relationships with J&J or any J&J subsidiary? (e.g., a paid speaker or consultant to any J&J products, engaged in J&J company sponsored research, engaged in a clinical study funded by a J&J Company, etc.)** vii. Will the HCP be involved in this research proposal/project?	Name: Position in Company: HCP License: ☐ Past ☐ Current Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No Please go to 9a.
9a. Are any key personnel (Board members, Officers of the Company, key employees) an HCP?	☐ Yes. Please go to 9b. ☐ No. Please go to 10a.

9b. If so, please provide the names of these HCPs and details of their economic interest and position with your company. **i. Is the HCP licensed and practicing?** **ii. Area of practice** **iii. % ownership of company** **iv. Current affiliations (e.g., hospitals, universities, ACOs, formulary committees, procurement committees, product review committees, product advisory committees, Boards, etc.)** v. Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products?	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐ Yes ☐ No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No

vi. Does the HCP have any prior or current relationships with J&J or any J&J subsidiary? (e.g., a paid speaker or consultant to any J&J products, engaged in J&J company sponsored research, engaged in a clinical study funded by a J&J Company, etc.) vii. Will the HCP be involved in this research proposal/project?	Name: Position in Company: HCP License: ☐ Past ☐ Current Is the HCP currently practicing? ☐ Yes ☐ No Area of Practice: Company Ownership: % Current Affiliations: Does the HCP have any influence on the use, recommendation, procurement or approval of J&J products? ☐ Yes. Please provide details. ☐ No Prior relationships with J&J: Current relationship with J&J (including J&J subsidiaries): Involved with research proposal/project? ☐ Yes ☐ No Please go to 10a.
10a. Are your company owners, partners, shareholders, or key decision makers a Government Official or affiliated with a Government Official?	☐ Yes. Please go to 10b. ☐ No. Please go to 11a.
10b. If 'Yes', please provide name(s) and the individual's(s') position(s).	Name: Position: Government Institution/Agency:
	Name: Position: Government Institution/Agency: Please go to 11a.

11a. Are your company owners, partners, shareholders, key decision makers currently working for a government-owned or a government-linked institution (e.g., a public hospital) which is or could potentially be a J&J customer? Note: This includes providing advisory, consulting or part-time services.	☐ Yes. Please go to 11b. ☐ No. Please go to 12a.
11b. If 'Yes", please provide name of the government-owned or government-linked institution(s).	Please go to 12a.
12a. Are any of the family members of the owners, principals, or board members of your company or your parent company employees of J&J?	☐ Yes. Please go to 12b. ☐ No
12b. If 'Yes', please provide details.	Name: Relationship:

COMPLETED BY	
Signature	
Name	
Date	

附件 B

Terms Sheet for Research Agreement and License Option

This term sheet (the "**Term Sheet**") sets forth the basic terms and conditions of the Research Agreement that the applicant ("**you**" or "**Institution**") will be required to agree to with Janssen Biotech Inc. ("**JBI**") or its affiliate (excluding JBI's affiliates in the People's Republic of China), and/or Industrial Technology Research Institute ("**ITRI**") (together, the "**Sponsors**") and execute as a condition to receiving research funding for the proposed research program.

Please review the basic terms and conditions of the Research Agreement detailed below. By signing the acknowledgement at the end of this Term Sheet, you are indicating that you accept the terms and conditions contained herein, subject to their incorporation together with all other terms and conditions in the Research Agreement. You also acknowledge that this Term Sheet does not contain all the terms and conditions to be included in the Research Agreement and the Sponsors reserve the right to include additional terms and conditions not specified herein in the Research Agreement.

For clarity, you are not required to acknowledge your agreement to the terms and conditions set forth in this Term Sheet as a condition to applying for the research funding. However, the Sponsors will consider whether you have acknowledged and agreed to the terms and conditions set forth in this Term Sheet when selecting potential candidates to receive research funding.

Parties	• JBI or its affiliate (excluding JBI's affiliates in the People's Republic of China) • ITRI • Applicant ("**Institution**")
Research Program	• Institution will conduct the research in accordance with the timelines, milestones, and deliverables set forth in the mutually agreed upon research program. • The parties will establish a joint steering committee, with equal membership from each party, to monitor the progress of the research program, to review research results, and to modify the research program by unanimous decision. • Research funding will be provided in accordance with an agreed-upon budget and payment schedule and will be used exclusively for the research.

	• Institution may not obtain any other funding to conduct the research without each Sponsor's consent. • Except as otherwise provided in its proposals received by selection committee, Institution may not engage any subcontractors or collaborators without each Sponsor's consent. • Institution will obtain and maintain adequate insurance to cover any liability arising from its conduct of the research. • Each Sponsor may terminate the research program for any reason upon thirty (30) days' notice or immediately at any time if the Sponsors are not satisfied with the progress of the research.
Principal Investigator	• Institution will designate a principal investigator to conduct and directly supervise the research program. • Each Sponsor may terminate the research program in the event the principal investigator ceases to be involved in the research program or Institution is unable to find a replacement principal investigator acceptable to each Sponsor.
Research Agreement	
Ownership of Program Technology	• For the avoidance of doubt, JBI does not intend to contribute any technology to Institution to conduct research, provided however, in the event that there is any dispute with regard to whether JBI has contributed technology to a particular Institution or research program, such dispute shall be resolved by binding arbitration pursuant to the Governing Law/Dispute Resolution section below. • Ownership of all technology developed under the research program shall be determined based on inventorship, and for all other technology which inventorship does not apply, will be owned by Institution, except, if JBI provides any technology to Institution to conduct the research, JBI will own any technology that uses, is based on, or is an improvement to any JBI technology (regardless of inventorship, including such technology jointly developed by Institution and JBI, or developed solely by Institution).

	• Inventorship for purposes of the Research Agreement shall be determined in accordance with United States patent law.
Research License	• Institution grants to JBI a non-exclusive, worldwide, royalty-free, non-transferable, perpetual license under the program technology and related products owned by Institution (the "**Licensed Technology**") to make and use Licensed Technology solely for JBI's internal research or educational purposes (which may include research performed with one or more third party collaborators) (excluding the use of any Licensed Technology in clinical studies and in research sponsored by a business or for-profit entity (or an affiliate of a business or for-profit entity)) and to have any of the foregoing performed on JBI's behalf by a third party service Applicant.
JBI Right of First Negotiation and Trailing Right of First Refusal	• At the conclusion or termination of the research program, Institution will in good faith provide to JBI a data package containing sufficient information to enable JBI to (i) determine whether to exercise its right of first negotiation and (ii) negotiate for itself or its designee or assignee an exclusive, worldwide license to the Licensed Technology (the "**Data Package**"). Institution further agrees that it shall provide any supplemental information requested by JBI to facilitate JBI's determination on whether to exercise its right of first negotiation and to negotiate for itself or its designee or assignee the License. • <u>Right of First Negotiation</u>. Institution grants to JBI, for a period starting from the effective date of the Research Agreement and continuing until the day that is sixty (60) days following the delivery of the Data Package ("**ROFN Exercise Period**"), the exclusive option to negotiate for itself or its designee or assignee an exclusive, worldwide license to the Licensed Technology upon the terms set forth in the License section below ("**License**") (such option, the "**JBI Option**"). For the avoidance of doubt, the Institution and JBI acknowledge and agree that the terms set forth in the License section below are non-negotiable and any negotiations relating to the definitive License shall be limited to those matters not set forth below (subject to written waiver by JBI). In the event JBI exercises the JBI Option during the ROFN Exercise Period by delivery of written notice to Institution ("**Exercise Notice**"), Institution

	shall negotiate in good faith and exclusively with JBI and/or one or more affiliates of JBI for any such affiliate for a period of one hundred and eighty (180) days from the date of the Exercise Notice (the "**Exclusive Negotiation Period**") to enter into a License with the Institution. o From the effective date of the Research Agreement and until the expiration of the Exclusive Negotiation Period has ended, Institution may not (i) transfer any Licensed Technology to a third party, (ii) solicit, initiate, continue or engage in any negotiations or discussions (nor disclose or furnish to any other party any information concerning your assets or business in contemplation of a Transaction) relating to Licensed Technology, or consider or respond to any indication of interest, offer or proposal, to enter into any agreement or understanding to consummate a Transaction relating to Licensed Technology, or (iii) enter into any Transaction with a third party relating to Licensed Technology without the prior written consent of JBI. o "Transaction" shall mean any transaction (i) which would sell, license, transfer, assign or otherwise make available (A) any Rights in or to any of Institution's significant assets or a significant portion of Institution's assets (including, without limitation, any of the Rights (as defined below)) or (B) any of Institution's capital stock or other equity interest or (ii) which would involve any business combination or merger, in either case, involving Institution or any of Institution's Affiliates in their capacities as such. The term "Rights" shall include all inventions, developments, patents, patent applications, know-how or other proprietary rights or products owned, developed or acquired (whether through license or otherwise) by the Institution related to Licensed Technology. • Right of Last Refusal. For a period of one hundred twenty (120) calendar days following the expiration of the Exclusive

	Negotiation Period (the "**Tail Period**" and, the last date of such period, the "**Expiration Date**"), the Institution shall not consummate or agree to consummate a Transaction with any other party (a "**Third Party**") without first giving prompt notice thereof to JBI in writing (the "**Proposed Transaction Notice**") (i) specifying the pricing, terms, conditions and other material provisions of such proposed Transaction, (ii) identifying the proposed Third Party and (iii) providing a copy of a written agreement in principal or letter of intent setting forth the terms of such proposed Transaction, if any such written agreement or letter of intent exists. In the event that JBI elects to consummate a transaction upon the same pricing, terms, conditions and other material provisions as specified in the Proposed Transaction Notice, JBI shall have thirty (30) calendar days to so notify Institution and Institution shall use all reasonable commercial efforts to facilitate the consummation of such Transaction with JBI and/or its affiliates within sixty (60) calendar days following the receipt of such notification (such sixty (60) day period, the "**Negotiation Period**"). Notwithstanding the foregoing, upon the Expiration Date all rights relating to this Right of Last Refusal shall terminate and any Proposed Transaction Notice period or Negotiation Period, together with all rights to receive Notices, to cause a Negotiation Period to occur and to receive any additional Proposed Transaction Notices based on changes in transaction terms, shall terminate upon the Expiration Date. • The Parties hereby acknowledge and agree that the Parties shall have no obligation (in each party's sole discretion) to enter into a definitive agreement concerning a Transaction. Institution hereby represents and warrants to JBI that the granting of the Right of First Negotiation, Right of Last Refusal and other terms provided herein will not conflict with or infringe upon the rights of any other person or entity.
Termination	• In the event of the expiration of the term or any termination of the Research Agreement, all unused funds shall be promptly returned to the Sponsors.

Governing Law/Dispute Resolution	• The Research Agreement will be governed by the laws of the State of New York. • The parties will resolve any disputes arising from the Research Agreement via arbitration in Hong Kong according to the rules of the Hong Kong International Arbitration Center.
License	
	• Institution will grant to JBI an exclusive, worldwide, royalty-bearing, sub-licensable license under the Licensed Technology to develop, manufacture, and commercialize the Licensed Technology and related products in any field. • JBI and Institution will each appoint an alliance manager to be the point of contact and to coordinate between the parties.
Development and Commercialization	• JBI will, in its sole discretion, determine whether to develop and commercialize the Licensed Technology and related products. • JBI will be solely responsible for all decisions regarding the development, manufacturing, and commercialization of the Licensed Technology and related products. • JBI will pay to Institution certain milestones and royalties as determined by the Parties following JBI's exercise of the JBI Option, subject to customary royalty-reductions for generic entry, loss of patent rights, and third-party obligations. • The royalty term will terminate, on a product-by-product and country-by-country basis, upon the earliest of (i) the expiration of the latest to expire of Institution's patents covering the Licensed Technology, (ii) the expiration of any data exclusivity, or (iii) 10 years after the first commercial sale of a related product. • Institution will have customary audit rights. • Institution will provide customary representations and warranties regarding the Licensed Technology, including non-infringement.
Ownership of Technology Developed Under the Exclusive License	• JBI will own any technology and intellectual property developed in connection with the development, manufacturing, and commercialization of the Licensed

	Technology and related products and will be solely responsible for filing, prosecuting, and maintaining any patent rights.
Governing Law/Dispute Resolution	• The License will be governed by the laws of the State of New York. • The parties will resolve any disputes arising from the License via arbitration in Hong Kong according to the rules of the Hong Kong International Arbitration Center.

ACKNOWLEDGED AND AGREED

By: _____

Name:

Organization:

Title:

附件 C

Statement Against Corrupt Practices

Compliance with Anti-Corruption Laws

Notwithstanding anything to the contrary in the Research Agreement, Applicant hereby agrees that:

(i) Applicant has not and shall not perform any actions that are prohibited by local and other anti-corruption laws (collectively "Anti-Corruption Laws") that may be applicable all parties to the Research Agreement;

(ii) Applicant has not and shall not, directly or indirectly, make any payment, or offer or transfer anything of value, or agree or promise to make any payment or offer or transfer anything of value, to a government official or government employee, to any political party or any candidate for political office or to any other third party related to the transaction with the purpose of influencing decisions related to Johnson & Johnson (the "Company"), its affiliates and/or its business in a manner that would violate Anti-Corruption Laws;

(iii) Applicant has not and shall not retain any government official or government employee in the performance of the Research Agreement unless it has been approved by Company and, if necessary, by the competent authority or authorities and such government official's or employee's employer. Furthermore, Applicant shall immediately advise Company in writing in the event Applicant becomes aware that any person engaged in the performance of the Research Agreement becomes a government official or employee, a political party official or a candidate for political office. The requirements of this subsection shall not apply with respect to employees of an Applicant that is a government owned entity;

(iv) Applicant shall designate an individual within its organization to receive training from Company on Anti-Corruption Laws as well as applicable rules on interactions with health care professionals, as mutually agreed to by the parties. Such designated individual shall then provide such training on Anti-Corruption Laws, using applicable training materials to be provided by Company, on at least an annual basis to all persons employed by Applicant who perform work in connection with the Company and interact with government officials or health care professionals in the normal course of their responsibilities. Upon Company's and Applicant's mutual agreement, such training may also be provided directly by Company to such employees of Applicant. Applicant shall also provide such training or training materials to any subcontractors it uses in the performance of the Research Agreement (to the extent the use of such subcontractors by Intermediary is permitted under the Research Agreement.) Any

training and materials provided by Company does not relieve Applicant of any obligations it has independent of the Research Agreement and Applicant shall not rely on Company's training and materials for any such obligations;

(v) Applicant shall certify on an annual basis in a format to be provided by Company that:

a. training and training materials on Anti-Corruption Laws as well as applicable rules on interactions with health care professionals, have been provided to all persons employed by Applicant who perform work for Company and interact with government officials or health care professionals in the normal course of their responsibilities and that it has provided the Company training and training materials to subcontractors used by Applicant in the performance of the Research Agreement;

b. to the best of Applicant's knowledge, there have been no violations of Anti-Corruption Laws by Applicant or persons employed by or subcontractors used by Applicant in the performance of the Research Agreement;

c. personnel of Applicant who may be designated as "Key Personnel" by mutual agreement of Company and Applicant have not changed, except as noted in a schedule attached to the certification provided by Applicant;

d. Applicant has made no changes in its use of subcontractors to perform the services for the Company under the Research Agreement, except as (1) permitted under the Research Agreement and (2) noted in a schedule attached to the certification provided by Applicant; and

e. Applicant has maintained true and accurate records necessary to demonstrate compliance with the requirements of this Exhibit.

(vi) Applicant shall maintain and provide Company and its auditors and other representatives with access to records (financial and otherwise) and supporting documentation related to the subject matter of the Research Agreement as may be requested by Company in order to document or verify compliance with the provisions of this Exhibit; and

(vii) if Applicant fails to comply with any of the provisions of this Exhibit, such failure shall be deemed to be a material breach of the Research Agreement and, upon any such failure, Company shall have the right to terminate the Research Agreement with immediate effect upon written notice to Applicant without Company having any financial liability or other liability of any nature whatsoever resulting from any such termination.

ACKNOWLEDGED AND AGREED

By: _____

Name:

Organization:

Title:

附件 D

Statement of Compliance with Federal Animal Welfare Regulations

Notwithstanding anything to the contrary in the Research Agreement, Applicant hereby agrees that:

In the event of a necessary relocation, Applicant must immediately contact JRD.

The Applicant represents and warrants that the procurement, delivery, preparation, supply, housing, care, and disposition of animals or animal tissues used for the purposes stated in the Research Agreement shall be in compliance with all applicable laws, regulations, governmental guidelines, and industry standards with respect to laboratory animal welfare and safeguarding of animal welfare, such as, but not limited to (i) the United States Animal Welfare Act, (ii) the rules and regulations of the National Institutes of Health (NIH), U.S. Department of Agriculture (USDA), or other governmental agencies; (iii) any guidelines, rules and regulations of the European Union and its national regulations; (iv) the Regulations for the Administration of Affairs Concerning Experimental Animals of the country in which Applicant locates and other applicable laws, regulations or governmental guidelines thereof , or (v) the law of any other jurisdiction as may apply.

Applicant shall be the owner of any animals used hereunder at all times and it shall obtain the approval/license/certificate for all activities involving animals from the appropriate Ethics Committee or regulatory authority. Ethics Committee shall mean the ethical committee responsible for overseeing animal care and use, which may include, but is not limited to, the Institutional Animal Care and Use Committee (IACUC) for US companies, an Ethics Committee on Animal Experiments (ECAE), and/or Animal Welfare Body for European companies.

Applicant shall not initiate any activity involving live animals unless the protocol used for the activity has been reviewed and approved by Applicant's Ethics Committee. A copy of such approval decision shall be provided to Janssen upon request.

When live animals are to be used in conjunction with the activity, the Applicant agrees to treat such animals humanely and use only humane and appropriate methods of euthanasia such as those described in the American Veterinary Medical Association (AVMA) guidelines on euthanasia, those established under the EU legislation on the protection of animals used for scientific purposes, or those established under the laws of any other jurisdiction as may apply. The Applicant's failure to abide by these requirements in connection with the delivery of animal related service shall be deemed a material breach and be grounds for Janssen's termination of this agreement.

Applicant represents and warrants that it understands that the Janssen expects its external service Applicants to follow the same standards as described in the J&J Policy on The Humane Care & Use of Animals, which is included in Attachment 1 attached.

If Applicant is AAALAC accredited.

Applicant represents and warrants that the facility where the activities involving animals are being conducted is AAALAC accredited. Applicant shall maintain its accredited status for the facilities listed within the agreement for the duration of the Research Agreement. Applicant shall immediately notify Janssen if a facility's AAALAC accreditation is not continuously maintained for any reason. Janssen (or Janssen's authorized representative) may inspect the facility where the activities involving animals are being conducted and review Applicant's animal care and use program. Applicant will cooperate with Janssen (or Janssen's authorized representative) during inspection and review.

If Applicant is not AAALAC accredited.

If the facility where the activities involving live animals are intended to be conducted is not currently accredited by AAALAC, Applicant will permit Janssen (or Janssen's authorized representative) access to the facility where the activities are intended to be conducted in order to evaluate the Applicant's animal care and use program. Applicant will cooperate with Janssen (or Janssen's authorized representative) during the evaluation and review.

Reporting

The Applicant agrees to provide a report with animal usage information to Janssen as requested, but no less than once annually. Such report should include all live animals which have been entered into the respective study(ies)/activities in the prior year, and at a minimum will contain at least the name and reference number of the protocol, animal species, number of animals used, start and end date, and the Applicant's contact person. An example of the reporting document is included in Attachment 2 attached. Additional information may be requested as agreed upon by the parties.

ACKNOWLEDGED AND AGREED

By: _____

Name:

Organization:

Title:

ATTACHMENT 1

Johnson & Johnson

Policy on the Humane Care & Use of Animals

Johnson & Johnson have a responsibility to ensure the ethical and humane treatment of animals that are used to advance patient safety and well-being. The care and use of laboratory animals in biomedical procedures is highly regulated. In general, the regulations govern procurement, housing, feeding, veterinary care, research project review, and require both internal and external inspections. Our companies have clear, well-developed policies and guidelines in place that mandate and drive the ethical and humane treatment of the animals we use, and that promote the use of non-animal alternatives whenever possible. We support and participate in efforts to obtain regulatory acceptance of any alternative testing methods. Our standards for animal care and use meet or exceed all applicable local, state and national laws and regulations.

Our corporation is committed to the "3R" Principles

•• Replacement –Using alternative non-animal systems in place of live animal utilization whenever possible

•• Reduction – Using the minimum number of animals possible to achieve maximum information without compromising animal welfare

•• Refinement – Continually modifying procedures to limit the discomfort and distress to animals

Institutional Animal Care and Use Committee (IACUC)/Ethical Review

•• Proposed Animal studies must be reviewed and approved by an IACUC or equivalent Ethical Committee.

Personnel Training – Competency

•• Personnel involved with the care and use of animals must be educated, trained, and/or qualified in the principles of animal welfare and compliance to help ensure quality science and animal well-being.

Sourcing Animals & Tissue

•• Live animals, preferably bred and raised specifically for research, and animal tissue used in research and teaching shall be obtained only from appropriate sources.

•• Euthanasia: Only humane and appropriate methods of euthanasia will be used, such as those described in the American Veterinary Medical Association (AVMA) guidelines on euthanasia and those established under the EU legislation on the protection of animals used for scientific purposes.

Teaching & Education

•• Live animals shall only be used when actual participation by the trainee is required to learn a medical or surgical procedure (including proper product usage) where alternate models have been deemed inadequate for the purpose.
•• We are committed to continually seek ways to refine training requirements that yield additional reductions in the use of animals in testing.

Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC)

•• We require that all Johnson & Johnson Animal facilities be AAALAC accredited.
•• Newly acquired non-accredited companies are expected to apply for accreditation

External Service Applicants

•• Johnson & Johnson expects the standards for animal care & use for external service Applicants to follow the same standards as described in this document.

◊ Standards for animal care and use will meet or exceed all applicable local, state and national laws and regulations.

◊ Johnson & Johnson preference is to work with external service Applicants that are AAALAC accredited. In cases where non-accredited external service Applicant use is justified, established Johnson & Johnson procedures must be followed and complied with to assure that such facilities meet Johnson & Johnson standards.

Cosmetics

•• The Johnson & Johnson Family of Consumer Companies does not test cosmetic products or ingredients on animals and we do not ask others to test on our behalf, except in those cases where testing is required by law or government regulations.

ATTACHMENT 2

Institution/CRO Name, Location, Country	Contractor's Contact	J&J Op CO	J&J Contact	Protocol / Study ID	Protocol / Study Title	Species	# of Animals	Study / Activity Start date	Study / Activity Term date

附件 E

Notification and Consent Regarding Collection, Processing and Use of Personal Information

Notification

In order to collect, process, and use your personal information which you have provided or will provide (hereinafter referred to as "the Personal Information"), based on the reason that you are participating in "ITRI-Janssen Joint Grant Call 2020", SPONSORS would like to inform you about the following matters:

A. Purposes for collection: Industry-Academy Cooperation Management

B. Classification of the Personal Information: Type for identifying individuals. (For the principal researcher of the Proposal which will be submitted to the Event, "details about your other family members", and "Professional and Technical Personnel Management" may be needed according to Exhibit A.)

C. Time period of the use of the Personal Information: until the purposes for collecting the information no longer exists.

D. Areas of use of the Personal Information: The territory of the ROC and SPONSORS's overseas locations and offices.

E. Users of the Personal Information: SPONSORS as well as government agencies and non-government agencies that have or will have business relations with SPONSORS.

F. Way of the use of the Personal Information: Under the condition that there is no excess of the scope of the purposes for which the Personal Information was collected, the Personal Information may be used on the Internet, in e-mail, in documents, in facsimiles, and in other lawful ways.

G. You may exercise the following rights by raising written request(s):

1. any inquiry and request for a review of the Personal Information;
2. any request to make duplications of the Personal Information;
3. any request to supplement or correct the Personal Information;
4. any request to discontinue collection, processing or use of the Personal Information; and
5. any request to delete the Personal Information.

H. If you do not sign this Notification and Consent Regarding Collection, Processing and Use of Personal Information, SPONSORS may not be able to contact with you.

I. SPONSORS will keep your Personal Information confidential and in proper custody in accordance with the relevant laws and regulations of the ROC.

Consent

I have read and understood the Notification set forth above, and hereby agree that SPONSORS may, within the scope of and in conformity with the contents of said Notification, collect, process and use the Personal Information. This consent may be expressed in the way of an electronic document.

The Party: _____

Name :

Address :

ID Number :

Date :

Janssen-Taiwan 合作計畫 - 2020 徵案說明會

主辦單位： Janssen Biotech, Inc.

工業技術研究院

活動說明：

美國 Janssen Biotech, Inc.（Janssen）為追求阻斷疾病、早期治療的理想，也為了整合技術創新與商業模式，擬借重台灣研發能量共同進行研發計畫。因此，Janssen 將與政府共同投入經費執行前瞻疾病治療計畫-「Janssen-Taiwan 合作計畫」，並由工研院協助執行，希望透過共同徵案激發研發能量，進而提升台灣生醫產業相關技術創新之附加價值與國際競爭力。

為了讓產學研各界更加了解「Janssen-Taiwan 合作計畫」，工研院將分別於新竹、台北舉辦說明會，邀請全台各大學院校及相關企業一同參與，歡迎對提案有興趣的人士，報名蒞臨參加！

說明會議程：

時間	議程
14:00～14:30	報到
14:30～15:30	「Janssen-Taiwan 合作計畫」徵案說明

舉辦時間暨地點：

新竹場次

時間：3/12(四)14:00-15:30

地點：**工業技術研究院光復院區 1 館 804 室**(新竹市光復路 2 段 321 號)

報名網址：https://college.itri.org.tw/course/all-events/A6C25D5A-731D-4122-8F3B-5710DE10EB17.html?utm_medium=crssearch&utm_source=college

台北場次

時間：3/16(一)14:00-15:30

地點：**科技大樓 4002 教室**(台北市和平東路二段 106 號 4 樓)

報名網址：https://college.itri.org.tw/course/all-events/63544A03-BB04-4622-AC81-B114F8EC679A.html?utm_medium=crssearch&utm_source=college

相關徵案資料：https://jti.itri.org.tw/index.aspx

注意事項：

因應 2019 新型冠狀病毒疫情，工研院辦理說明會相關防疫措施說明如下，敬請配合：

1. 請填寫健康聲明書(會前提供)，若有任何呼吸道症狀或於過去 14 天自中港澳、韓國、新加坡、日本、泰國、伊朗、義大利及其他國家返台或 14 天內有前述地區返台人員接觸史者，請主動告知工作人員。
2. 課程報到時請量測體溫，若有發燒現象(38 度(含)以上)不予以進入教室。
3. 14 天內自日本、新加坡、泰國、伊朗、義大利返國者或與返台之親友接觸者，請一律配戴口罩(管制地區將依中央流行疫情指揮中心公布隨之調整執行)。
4. 請自主管理身體健康，如出現咳嗽等呼吸道症狀應配戴口罩，並落實勤洗手、呼吸道衛生與咳嗽禮節。

如有任何疑問，請向主辦單位聯絡窗口詢問：

聯絡人：邱小容　工業技術研究院/JTI 計畫辦公室

電話：（03）591-3740　E-Mail：jtioffice@itri.org.tw

地址：新竹縣竹東鎮中興路 4 段 195 號 52 館 135 室